Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2023 16:00 ET | Source: FibroGen, Inc.

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancersCollaboration expands FibroGen’s clinical pipeline with potential...